Patient and transplantation characteristics
| Case no. . | Age, y . | Sex, R/D . | Diagnosis . | Conditioning/stem cell source . | GVHD prophylaxis . | aGVHD grade . | cGVHD . | cGVHD sites . | Immunosuppression before imatinib . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 34.7 | F/M | CML | MAC/BM | CSA | 1 | Extensive | Skin, joint contracture | CS-CSA |
| 2 | 15.3 | M/M | CML | RIC/BM | CSA-MMF | 3 | Extensive | Skin, mouth, eyes | CS-CSA-AZA-MMF |
| 3 | 53.6 | M/F | MDS | MAC/BM | CSA-MTX | None | Extensive | Skin, bronchiolitis, joint contracture | CS-CSA-MMF-RTX-ECP |
| 4 | 45.1 | M/M | HODG | RIC/PBSC | CSA-MMF | None | Extensive | Skin, mouth | CS-CSA-MMF |
| 5 | 59 | M/M | CML | RIC/PBSC | CSA-MMF | 2 | Extensive | Skin, mouth | CS-TAC-MMF |
| 6 | 54.6 | F/F | MDS | MAC/PBSC | CSA-CS | None | Extensive | Skin, eyes, mouth | CS-CSA-MMF-RTX-ECP |
| 7 | 56.3 | F/M | MDS | MAC/BM | CSA-MTX | 2 | Extensive | Skin, mouth | CS-ECP |
| 8 | 31 | F/M | AA | MAC/PBSC | CSA-CS-MMF | None | Extensive | Skin, mouth, eyes, bronchiolitis, joint contracture | CS-TAC-MMF |
| 9 | 25.6 | M/F | ALL | MAC/BM | TAC-CS-MMF | None | Extensive | Skin, mouth, joint contracture | CS-CSA-MMF-TAC-ECP |
| 10 | 22.8 | M/F | ALL | MAC/BM | CSA-CS | 1 | Extensive | Skin, mouth, liver | CS-CSA-ECP |
| 11 | 35.2 | F/F | HODG | RIC/PBSC | SIR-MMF | None | Extensive | Skin, mouth | CS-CSA-MMF-ECP |
| 12 | 4.7 | F/F | AML | MAC/BM | CSA-MTX | None | Extensive | Joint contracture without sclerotic lesions | CS-CSA-MMF-ECP |
| 13 | 52 | M/M | MMM | RIC/PBSC | CSA | None | Extensive | Skin, mouth, eyes, joint contracture | CS-CSA-MMF-RTX |
| 14 | 56 | M/F | MMM | MAC/BM | CSA-MMF | None | Extensive | Skin, mouth, eyes, liver, joint contracture | CS-CSA-MMF-RTX |
| Case no. . | Age, y . | Sex, R/D . | Diagnosis . | Conditioning/stem cell source . | GVHD prophylaxis . | aGVHD grade . | cGVHD . | cGVHD sites . | Immunosuppression before imatinib . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 34.7 | F/M | CML | MAC/BM | CSA | 1 | Extensive | Skin, joint contracture | CS-CSA |
| 2 | 15.3 | M/M | CML | RIC/BM | CSA-MMF | 3 | Extensive | Skin, mouth, eyes | CS-CSA-AZA-MMF |
| 3 | 53.6 | M/F | MDS | MAC/BM | CSA-MTX | None | Extensive | Skin, bronchiolitis, joint contracture | CS-CSA-MMF-RTX-ECP |
| 4 | 45.1 | M/M | HODG | RIC/PBSC | CSA-MMF | None | Extensive | Skin, mouth | CS-CSA-MMF |
| 5 | 59 | M/M | CML | RIC/PBSC | CSA-MMF | 2 | Extensive | Skin, mouth | CS-TAC-MMF |
| 6 | 54.6 | F/F | MDS | MAC/PBSC | CSA-CS | None | Extensive | Skin, eyes, mouth | CS-CSA-MMF-RTX-ECP |
| 7 | 56.3 | F/M | MDS | MAC/BM | CSA-MTX | 2 | Extensive | Skin, mouth | CS-ECP |
| 8 | 31 | F/M | AA | MAC/PBSC | CSA-CS-MMF | None | Extensive | Skin, mouth, eyes, bronchiolitis, joint contracture | CS-TAC-MMF |
| 9 | 25.6 | M/F | ALL | MAC/BM | TAC-CS-MMF | None | Extensive | Skin, mouth, joint contracture | CS-CSA-MMF-TAC-ECP |
| 10 | 22.8 | M/F | ALL | MAC/BM | CSA-CS | 1 | Extensive | Skin, mouth, liver | CS-CSA-ECP |
| 11 | 35.2 | F/F | HODG | RIC/PBSC | SIR-MMF | None | Extensive | Skin, mouth | CS-CSA-MMF-ECP |
| 12 | 4.7 | F/F | AML | MAC/BM | CSA-MTX | None | Extensive | Joint contracture without sclerotic lesions | CS-CSA-MMF-ECP |
| 13 | 52 | M/M | MMM | RIC/PBSC | CSA | None | Extensive | Skin, mouth, eyes, joint contracture | CS-CSA-MMF-RTX |
| 14 | 56 | M/F | MMM | MAC/BM | CSA-MMF | None | Extensive | Skin, mouth, eyes, liver, joint contracture | CS-CSA-MMF-RTX |
R/D indicates recipient/donor; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; CML, chronic myeloid leukemia; MAC, myeloablative conditioning; BM, bone marrow; CSA, cyclosporine A; CS, corticosteroids; RIC, reduced intensity conditioning; MMF, mycophenolate mofetil; AZA, azathioprine; MDS, myelodysplastic syndrome; MTX, methotrexate; RTX, rituximab; ECP, extracorporeal photopheresis; HODG, Hodgkin disease; PBSC, peripheral blood stem cell; AA: aplastic anemia; TAC, tacrolimus; ALL, acute lymphoblastic leukemia; SIR, sirolimus; AML, acute myeloid leukemia; and MMM, myeloid metaplasia with myelofibrosis.